Skip to search formSkip to main contentSkip to account menu

nifekalant hydrochloride

Known as: 1,3-dimethyl-6-((2-(N-(2-hydroxyethyl)-3-(4-nitrophenyl)propylamino)ethylamino)-2,4(1H),3H)-pyrimidinedione hydrochloride 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

nifekalant

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Crystallization granuloma by nifekalant hydrochloride infusion
Tomoko Yamada, Shin-ichiro Iwakami, Sumiko Abe Munechika Hara, Naoko Iwakami, Ai Nakamura, Yoshifumi Suzuki, Shin-ichi Sasaki and… 
2010
2010
Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm.
udden cardiac arrest is a major public health problem worldwide and despite decades of efforts to promote cardiopulmonary… 
2010
2010
Nifekalant hydrochloride terminated electrical storms after coronary surgery.
2007
2007
[Successful administration of nifekalant hydrochloride for postoperative junctional ectopic tachycardia in congenital cardiac surgery].
Two episode of junctional ectopic tachycardia (JET) caused hemodynamic deterioration early after tetralogy of Fallot repair in an… 
2004
2004
Electropharmacological and Proarrhythmic Effects of a Class III Antiarrhythmic Drug Nifekalant Hydrochloride Assessed Using the In Vivo Canine Models
Abstract: Cardiovascular effects of Nifekalant were examined using halothane-anesthetized dogs, and its proarrhythmic potential… 
2004
2004
Determination of nifekalant hydrochloride and related impurities by HPLC
Objective To establish a new HPLC method for determination the content of nifekalant hydrochloride and nifekalant hydrochloride… 
2004
2004
Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation.
A 52-year-old male with ischemic cardiomyopathy and severe ventricular dysfunction underwent coronary artery bypass grafting and… 
2003
2003
Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor…
A patient with 3-vessel coronary artery disease and left ventricular aneurysm underwent coronary artery bypass grafting combined… 
Review
2002
Review
2002
Anti-arrhythmic Efficacy of Nifekalant Hydrochloride, a Pure Class III Anti-arrhythmic Agent, in Patients With Healed Myocardial Infarction and Inducible Sustained Ventricular Tachycardia
In recent clinical trials, class III anti-arrhythmic drugs were found to reduce arrhythmic deaths in patients after myocardial… 
2001
2001
Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)